Boehringer Ingelheim, Lilly (LLY) Receive FDA Approval for Tradjenta sNDA as Add-On to Insulin Therapy
Go back to Boehringer Ingelheim, Lilly (LLY) Receive FDA Approval for Tradjenta sNDA as Add-On to Insulin Therapy| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1225.73 +42.57 (3.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1183.16 | 52 Week High | $88.16 | |||
| Open | $1200.00 | 52 Week Low | $67.88 | |||
| Day High | $1228.47 | P/E | 283.73 | |||
| Day Low | $1194.01 | EPS | $4.32 | |||
| Volume | 2,508,478 | |||||
